Related Experiment Video
Updated: Jan 20, 2026

mRNA Interactome Capture from Plant Protoplasts
Published on: July 28, 2017
Maximizing binary interactome mapping with a minimal number of assays
Soon Gang Choi1,2,3, Julien Olivet1,2,3,4, Patricia Cassonnet5
1Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute (DFCI), 450 Brookline Avenue, Boston, MA, 02215, USA.
Optimally combining protein-protein interaction (PPI) assay versions, like our novel NanoLuc two-hybrid (N2H) system, enhances mapping completeness and precision. This strategy recovers as many interactions as multiple distinct assays combined.
Area of Science:
- Molecular Biology
- Biochemistry
- Systems Biology
Background:
- Comprehensive mapping of biological entities like proteomes requires complementary assays.
- Optimizing the combination of different assays for maximal coverage and precision is challenging.
Purpose of the Study:
- To propose a framework for binary protein-protein interaction (PPI) mapping by optimally combining assay versions.
- To maximize the detection of true positive PPIs while minimizing false positives.
Main Methods:
- Engineered a novel NanoLuc two-hybrid (N2H) system integrating 12 distinct versions.
- Varied protein expression systems and tagging configurations within the N2H system.
Main Results:
- The union of N2H versions recovered as many PPIs as 10 distinct assays combined.
- Demonstrated that optimizing assay versions can be as effective as developing new assays for PPI mapping.
Conclusions:
- Developing alternative versions of existing assays is a productive strategy for improving PPI mapping.
- The proposed framework and findings are applicable to systematic mapping of other biological landscapes.
Related Concept Videos
Binary Fission
Binary Fission
12:29mRNA Interactome Capture from Plant Protoplasts
Establishing a Binary Culture of Saccharibacteria with Host Bacteria
Profit Maximization vs. Wealth Maximization
In contrast, wealth maximization aims to increase the...
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms